Results 101 to 110 of about 349,757 (388)

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

Molecular Cancer Therapeutics, 2018
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd), has been reported to exert potent antitumor effects in xenograft mouse models and clinical trials.
T. Iwata, Chiaki Ishii, S. Ishida, Y. Ogitani, T. Wada, T. Agatsuma   +5 more
semanticscholar   +1 more source

High-Level Expression of Various Apolipoprotein (a) Isoforms by "Transferrinfection". The Role of Kringle IV Sequences in the Extracellular Association with Low-Density Lipoprotein [PDF]

, 1994
Characterization of the assembly of lipoprotein(a) [Lp(a)] is of fundamental importance to understanding the biosynthesis and metabolism of this atherogenic lipoprotein. Since no established cell lines exist that express Lp(a) or apolipoprotein(a) [apo(a)
Azrolan N., Boerwinkle E., Brunner C., Chiesa G., Chung B. Y., Cotten M., Deutscher S. L., Deutscher S. L., Dieplinger H., Edelberg J. M., Green S., Griffiths G., Guevara J., Jr., Huby T., Ichinose A., Kamboh M. I., Koschinsky M. L., Koschinsky M. L., Koschinsky M. L., Kostner G. M., Kraft H- G., Kraft H. G., Krempler F., Krempler F., Lackner C., Linton M. F., Malgaretti N., McGregor G. R., McLean J. W., Menzel H. J., Phillips M. L., Rader D. J., Sambrook J., Sandholzer C., Scanu A. M., Selden R. F., Sommer A., Stanley P., Trieu V. N., Utermann G., Utermann G., Utermann G., Wagner E., White A. L., Zatloukal K., Zechner R„   +45 more
core   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy, 2019
Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA ...
Lai C, Kandahari AM, Ujjani C
doaj  

Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

Scientific Reports
This study aimed to design a VEGFR-targeting peptide–drug conjugate with the ability to decrease tumor burden and suppress tumor angiogenesis, and to further evaluate the therapeutic effect of anti-PD-1 antibody in HCC therapy.
Jiacheng Liu, Yaowei Bai, Xiaoming Liu, Binqian Zhou, Peng Sun, Yingliang Wang, Shuguang Ju, Chen Zhou, Chaoyang Wang, Wei Yao, Huihui Yang, Xin Jiang, Lian Yang, Dongyuan Wang, Chuansheng Zheng   +14 more
doaj   +1 more source

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. [PDF]

, 2014
IntroductionThe purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or ...
Amler, Lukas C, Gianni, Luca, Guardino, Ellie, Hurvitz, Sara A, Mundt, Kirsten E, Ng, Vivian, Perez, Edith A   +6 more
core   +3 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Antibody Drug Conjugates for Cancer Therapy

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017
BACKGROUND AND OBJECTIVE: In recent decades, the use of antibody drugs conjugates (ADCs) generated promise for the treatment of cancer. In this type of treatment, a monoclonal antibody against a cancer specific antigen is used, and a cytotoxic drug is ...
S M Gheibi hayat, AH Sahebkar
doaj  

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Science Translational Medicine, 2019
ALK is a tractable antibody-drug conjugate target in neuroblastoma. No neuroblastomas left behind Anaplastic lymphoma kinase (ALK) is frequently expressed in neuroblastoma, one of the more common pediatric cancers.
R. Sano, K. Krytska, C. Larmour, Pichai Raman, D. Martinez, G. Ligon, J. Lillquist, U. Cucchi, P. Orsini, S. Rizzi, B. Pawel, Diego Alvarado, Y. Mossé   +12 more
semanticscholar   +1 more source

Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan [PDF]

, 2015
The aim of this overview is to review the evolution of the studies carried out, during more than 25 years, on nanohydrogels obtained by self-assembling of pullulan (PUL) using several hydrophobization strategies.
ALHAIQUE, Franco, COVIELLO, Tommasina, DI MEO, Chiara, MATRICARDI, PIETRO, MONTANARI, ELITA   +4 more
core   +1 more source